PomDoctor and Inovio Face Class Action Lawsuits
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy INO?
Source: Globenewswire
- PomDoctor Class Action: PomDoctor, Ltd. (NASDAQ:POM) faces a class action lawsuit for the period from October 9, 2025, to December 11, 2025, alleging that the company failed to disclose a fraudulent stock promotion scheme involving social media, which has led to significant investor losses and could adversely affect the company's reputation and stock price.
- Insider Trading Allegations: The lawsuit claims that insiders used offshore accounts to facilitate stock dumping, and the failure to disclose this information has severely damaged the company's image among investors, potentially complicating future financing efforts.
- Inovio's Regulatory Challenges: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is facing a class action lawsuit for the period from October 10, 2023, to December 26, 2025, alleging that the company did not disclose deficiencies in the manufacturing of its CELLECTRA device, which jeopardizes the prospects of its Biologics License Application, leading to a decline in investor confidence.
- FDA Review Impact: Although Inovio's Biologics License Application was accepted by the FDA on December 29, 2025, the company failed to provide adequate information for accelerated approval, resulting in a 24.45% drop in stock price, reflecting market concerns about its future commercial prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.730
Low
3.00
Averages
7.33
High
13.00
Current: 1.730
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Multiple Companies Facing Class Action Lawsuits
- Oracle Lawsuit: Oracle Corporation is facing a class action lawsuit for the period from June 12 to December 16, 2025, due to its AI infrastructure strategy leading to significant capital expenditure increases, which could severely impact its debt and credit rating, with investor losses expected to exceed $50,000.
- Paysafe Risks: Paysafe Limited is being sued for the period from March 4 to November 12, 2025, for failing to disclose significant exposure to a single high-risk client in its e-commerce business, which is likely to negatively impact its revenue growth and may prevent it from meeting its financial guidance for fiscal year 2025.
- Inovio Pharmaceuticals Issues: Inovio Pharmaceuticals, Inc. is facing a class action lawsuit for the period from October 10, 2023, to December 26, 2025, due to deficiencies in manufacturing its CELLECTRA device, which is expected to hinder its ability to submit the INO-3107 BLA to the FDA by the second half of 2024, affecting its regulatory and commercial prospects.
- Kyndryl Financial Misstatements: Kyndryl Holdings, Inc. is being sued for the period from August 7, 2024, to February 9, 2026, due to materially misstated financial statements, which are expected to prevent timely filing of its Quarterly Report for the quarter ended December 31, 2025, raising concerns about its business outlook.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 2023 and December 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: The lawsuit alleges that Inovio made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which delayed the submission of the INO-3107 BLA to the FDA until mid-2025, undermining investor confidence.
- Stock Price Volatility: Following the announcement of the delayed BLA submission on August 9, 2024, Inovio's stock price fell by 3.1% to close at $8.44 per share; subsequently, on December 29, 2025, the stock plummeted by 24.45% to $1.73 per share after the FDA accepted the BLA for standard review instead of accelerated review.
- Investor Rights at Stake: The lawsuit highlights significant economic losses suffered by investors due to Inovio's misleading statements, with Pomerantz LLP, a leading firm in securities class action litigation, committed to advocating for the rights of affected investors and seeking compensation.
See More
Inovio Pharmaceuticals Shareholder Notice Issued
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Inovio Pharmaceuticals, encouraging those who purchased shares between October 10, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff status.
- Allegations Overview: The complaint alleges that Inovio made materially false or misleading statements during the class period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device, which jeopardizes the timeline for submitting INO-3107 to the FDA.
- Critical Deadline: Shareholders must register by April 7, 2026, to participate in the class action, emphasizing the urgency of the legal process and the potential impact on their rights to claim damages.
- No Cost Participation: Once registered, shareholders will receive portfolio monitoring updates throughout the case lifecycle, and participation incurs no costs, highlighting the accessibility and transparency of legal services offered by the firm.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegation: The complaint alleges that Inovio had manufacturing deficiencies with its CELLECTRA device and is unlikely to file the INO-3107 BLA by the second half of 2024, rendering the company's public statements throughout the class period false and misleading.
- Investor Losses: As the market learned the truth about Inovio, investors suffered damages, indicating the company's failure to provide sufficient evidence for FDA priority review or accelerated approval, which further eroded investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to discuss their rights, demonstrating the firm's commitment to protecting investor interests while reminding investors that they are not represented until the class action is certified.
See More
PomDoctor and Inovio Face Class Action Lawsuits
- PomDoctor Class Action: PomDoctor, Ltd. (NASDAQ:POM) faces a class action lawsuit for the period from October 9, 2025, to December 11, 2025, alleging that the company failed to disclose a fraudulent stock promotion scheme involving social media, which has led to significant investor losses and could adversely affect the company's reputation and stock price.
- Insider Trading Allegations: The lawsuit claims that insiders used offshore accounts to facilitate stock dumping, and the failure to disclose this information has severely damaged the company's image among investors, potentially complicating future financing efforts.
- Inovio's Regulatory Challenges: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is facing a class action lawsuit for the period from October 10, 2023, to December 26, 2025, alleging that the company did not disclose deficiencies in the manufacturing of its CELLECTRA device, which jeopardizes the prospects of its Biologics License Application, leading to a decline in investor confidence.
- FDA Review Impact: Although Inovio's Biologics License Application was accepted by the FDA on December 29, 2025, the company failed to provide adequate information for accelerated approval, resulting in a 24.45% drop in stock price, reflecting market concerns about its future commercial prospects.
See More
Inovio Pharmaceuticals Investors Class Action Notice
- Class Action Initiated: The Portnoy Law Firm advises Inovio Pharmaceuticals investors of a class action for those who purchased securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, for filing a lead plaintiff motion, indicating the urgency of legal action.
- False Statement Allegations: The lawsuit claims that throughout the class period, Inovio's management made false and misleading statements, failing to disclose manufacturing deficiencies in its CELLECTRA device, which misled investors regarding the prospects of the INO-3107 Biologics License Application, impacting investor decisions.
- FDA Review Developments: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but noted that the company did not provide adequate information to justify eligibility for accelerated approval, highlighting significant regulatory compliance challenges for Inovio.
- Stock Price Volatility: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting market pessimism regarding the company's prospects and resulting in substantial investor losses.
See More
Multiple Companies Facing Class Action Lawsuits
- Oracle Lawsuit: Oracle Corporation is facing a class action lawsuit for the period from June 12 to December 16, 2025, due to its AI infrastructure strategy leading to significant capital expenditure increases, which could severely impact its debt and credit rating, with investor losses expected to exceed $50,000.
- Paysafe Risks: Paysafe Limited is being sued for the period from March 4 to November 12, 2025, for failing to disclose significant exposure to a single high-risk client in its e-commerce business, which is likely to negatively impact its revenue growth and may prevent it from meeting its financial guidance for fiscal year 2025.
- Inovio Pharmaceuticals Issues: Inovio Pharmaceuticals, Inc. is facing a class action lawsuit for the period from October 10, 2023, to December 26, 2025, due to deficiencies in manufacturing its CELLECTRA device, which is expected to hinder its ability to submit the INO-3107 BLA to the FDA by the second half of 2024, affecting its regulatory and commercial prospects.
- Kyndryl Financial Misstatements: Kyndryl Holdings, Inc. is being sued for the period from August 7, 2024, to February 9, 2026, due to materially misstated financial statements, which are expected to prevent timely filing of its Quarterly Report for the quarter ended December 31, 2025, raising concerns about its business outlook.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 2023 and December 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: The lawsuit alleges that Inovio made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which delayed the submission of the INO-3107 BLA to the FDA until mid-2025, undermining investor confidence.
- Stock Price Volatility: Following the announcement of the delayed BLA submission on August 9, 2024, Inovio's stock price fell by 3.1% to close at $8.44 per share; subsequently, on December 29, 2025, the stock plummeted by 24.45% to $1.73 per share after the FDA accepted the BLA for standard review instead of accelerated review.
- Investor Rights at Stake: The lawsuit highlights significant economic losses suffered by investors due to Inovio's misleading statements, with Pomerantz LLP, a leading firm in securities class action litigation, committed to advocating for the rights of affected investors and seeking compensation.
See More
Inovio Pharmaceuticals Shareholder Notice Issued
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Inovio Pharmaceuticals, encouraging those who purchased shares between October 10, 2023, and December 26, 2025, to contact the firm regarding potential lead plaintiff status.
- Allegations Overview: The complaint alleges that Inovio made materially false or misleading statements during the class period, particularly regarding deficiencies in the manufacturing of its CELLECTRA device, which jeopardizes the timeline for submitting INO-3107 to the FDA.
- Critical Deadline: Shareholders must register by April 7, 2026, to participate in the class action, emphasizing the urgency of the legal process and the potential impact on their rights to claim damages.
- No Cost Participation: Once registered, shareholders will receive portfolio monitoring updates throughout the case lifecycle, and participation incurs no costs, highlighting the accessibility and transparency of legal services offered by the firm.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026.
- False Statements Allegation: The complaint alleges that Inovio had manufacturing deficiencies with its CELLECTRA device and is unlikely to file the INO-3107 BLA by the second half of 2024, rendering the company's public statements throughout the class period false and misleading.
- Investor Losses: As the market learned the truth about Inovio, investors suffered damages, indicating the company's failure to provide sufficient evidence for FDA priority review or accelerated approval, which further eroded investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to discuss their rights, demonstrating the firm's commitment to protecting investor interests while reminding investors that they are not represented until the class action is certified.
See More
PomDoctor and Inovio Face Class Action Lawsuits
- PomDoctor Class Action: PomDoctor, Ltd. (NASDAQ:POM) faces a class action lawsuit for the period from October 9, 2025, to December 11, 2025, alleging that the company failed to disclose a fraudulent stock promotion scheme involving social media, which has led to significant investor losses and could adversely affect the company's reputation and stock price.
- Insider Trading Allegations: The lawsuit claims that insiders used offshore accounts to facilitate stock dumping, and the failure to disclose this information has severely damaged the company's image among investors, potentially complicating future financing efforts.
- Inovio's Regulatory Challenges: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is facing a class action lawsuit for the period from October 10, 2023, to December 26, 2025, alleging that the company did not disclose deficiencies in the manufacturing of its CELLECTRA device, which jeopardizes the prospects of its Biologics License Application, leading to a decline in investor confidence.
- FDA Review Impact: Although Inovio's Biologics License Application was accepted by the FDA on December 29, 2025, the company failed to provide adequate information for accelerated approval, resulting in a 24.45% drop in stock price, reflecting market concerns about its future commercial prospects.
See More
Inovio Pharmaceuticals Investors Class Action Notice
- Class Action Initiated: The Portnoy Law Firm advises Inovio Pharmaceuticals investors of a class action for those who purchased securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, for filing a lead plaintiff motion, indicating the urgency of legal action.
- False Statement Allegations: The lawsuit claims that throughout the class period, Inovio's management made false and misleading statements, failing to disclose manufacturing deficiencies in its CELLECTRA device, which misled investors regarding the prospects of the INO-3107 Biologics License Application, impacting investor decisions.
- FDA Review Developments: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but noted that the company did not provide adequate information to justify eligibility for accelerated approval, highlighting significant regulatory compliance challenges for Inovio.
- Stock Price Volatility: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting market pessimism regarding the company's prospects and resulting in substantial investor losses.
See More
